Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 22,562 Shares
by Scott Moore · The Cerbat GemHeartflow, Inc. (NASDAQ:HTFL – Get Free Report) CEO John C.M. Farquhar sold 22,562 shares of the firm’s stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $26.72, for a total transaction of $602,856.64. Following the completion of the transaction, the chief executive officer directly owned 549,163 shares in the company, valued at $14,673,635.36. This represents a 3.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
John C.M. Farquhar also recently made the following trade(s):
- On Wednesday, March 18th, John C.M. Farquhar sold 9,725 shares of Heartflow stock. The stock was sold at an average price of $25.00, for a total value of $243,125.00.
- On Tuesday, March 10th, John C.M. Farquhar sold 12,837 shares of Heartflow stock. The shares were sold at an average price of $22.66, for a total value of $290,886.42.
- On Tuesday, February 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $27.46, for a total value of $619,552.52.
Heartflow Stock Performance
Shares of NASDAQ:HTFL traded up $1.62 during trading on Tuesday, reaching $29.05. The stock had a trading volume of 1,283,628 shares, compared to its average volume of 1,487,298. Heartflow, Inc. has a 1-year low of $20.13 and a 1-year high of $41.22. The stock has a market cap of $2.49 billion and a PE ratio of -14.60. The business has a fifty day moving average price of $24.69 and a 200-day moving average price of $29.59.
Institutional Trading of Heartflow
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP purchased a new position in shares of Heartflow during the 3rd quarter worth $164,263,000. Baillie Gifford & Co. purchased a new stake in shares of Heartflow in the third quarter valued at about $101,182,000. Schusterman Interests LLC acquired a new stake in Heartflow during the third quarter worth about $65,274,000. Capricorn Investment Group LLC purchased a new position in Heartflow during the fourth quarter worth about $48,178,000. Finally, Vanguard Group Inc. acquired a new position in Heartflow in the 3rd quarter valued at about $48,871,000.
Analysts Set New Price Targets
Several equities research analysts have issued reports on the stock. Canaccord Genuity Group lifted their target price on shares of Heartflow from $40.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. JPMorgan Chase & Co. decreased their price target on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, March 19th. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Finally, Wells Fargo & Company cut their price objective on shares of Heartflow from $38.00 to $35.00 and set an “overweight” rating for the company in a report on Thursday, March 19th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.
Read Our Latest Analysis on Heartflow
About Heartflow
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.